Illumina Launches TruPath Genome to Enhance Rare Disease Diagnostics
Event summary
- Illumina launched TruPath Genome on February 24, 2026, offering a more complete genome analysis with a simplified workflow.
- TruPath Genome delivers unparalleled accuracy and resolution, including difficult-to-map regions, variant phasing, and structural variants.
- The technology is priced at $395 USD per whole genome, including all consumables and analysis.
- Broad Clinical Labs is among the first adopters, with over 30 early access customers piloting the technology.
The big picture
Illumina's TruPath Genome launch addresses a critical need in rare disease diagnostics by providing comprehensive whole-genome insights. This technology positions Illumina to capture a larger share of the clinical genomics market, particularly in areas requiring high accuracy and resolution. The simplified workflow and cost-effective pricing could accelerate adoption among research institutions and clinical labs.
What we're watching
- Market Adoption
- How quickly Broad Clinical Labs and other early adopters integrate TruPath Genome into their research workflows.
- Competitive Positioning
- Whether Illumina can sustain its leadership in genomic sequencing with this new technology.
- Regulatory Approval
- The pace at which TruPath Genome gains regulatory approvals for clinical use.
Related topics